Can an fMRI Scan Prove Methamphetamine Impairment After Abstinence? What 54 Men’s Brain Networks Actually Showed

Quick answer: No. In a 2026 observational study, 25 men reporting approximately three to twelve months of methamphetamine abstinence had lower average cognitive screening scores and different resting-state brain signals than 29 healthy male controls. Within the abstinent group, a stronger calculated connection between the right hippocampus and right inferior temporal gyrus was associated with a higher Montreal Cognitive Assessment score. These results concern group neuroimaging associations, not chemically measured methamphetamine concentrations, a validated individual intoxication test, recovery time, impaired driving, or proof that methamphetamine caused a particular incident.

The original study was conducted by Yang, Hou, Zeng, Ling, Zhu, Xu, Wang, Lu, and Zhu and reported in BMC Psychiatry (2026), volume 26, article 710: Multi-metric resting-state fMRI reveals brain network abnormalities underlying cognitive impairment in male patients during methamphetamine abstinence. Its strength is the careful separation of several complementary imaging measures; its limitation is that none of them is a forensic chemical identification or person-level impairment assay.

What precise question did the experiment test?

The researchers asked whether men with a history of methamphetamine use disorder, who were currently abstinent, differed from healthy men in resting-state functional magnetic resonance imaging and in a brief cognitive screening measure. They evaluated local fluctuations, local synchrony, correlations between a prespecified right-hippocampal seed and other brain regions, and estimated organization of larger resting-state networks. They then examined whether selected brain-connectivity values covaried with cognitive screening performance, including whether some associations differed between the groups.

That question is not equivalent to asking whether an identified individual was recently intoxicated. The participants were not administered methamphetamine in the experiment. There was no pre- and post-dose concentration curve, no direct assay of methamphetamine in venous whole blood, and no on-road or simulated driving assessment. The right interpretation begins with the experimental design rather than with the apparent sophistication of the imaging equipment.

Who was included, and why is the denominator 54 rather than 60?

Thirty men with methamphetamine use disorder and thirty healthy male controls were recruited. Five patients and one control were excluded because of excessive motion or insufficient imaging data quality. The final analyses therefore used 25 abstinent patients and 29 controls, 54 distinct people. Thousands of image voxels, 230 acquired functional time points per scan, and multiple network features do not create additional independent study participants.

The mean ages were 36.36 years in the patient group and 35.86 in controls, with an age-comparison p-value of .843. Years of education averaged 10.08 and 10.55, respectively, with p=.299. These nonsignificant demographic comparisons do not demonstrate that every potentially relevant factor was balanced. All participants were male, and the clinical group had a history of a specific substance-use disorder; extrapolation to women, mixed-sex clinical populations, acute intoxication, or forensic referral populations would require further evidence.

How was abstinence determined, and could the study date someone’s last use?

The authors described self-reported continuous cessation for at least three months and within roughly the first year, supported by negative random urine toxicology screens at enrollment and on the MRI date. They did not obtain reliable exact cessation dates for a day-level abstinence-duration covariate. Nor did the published experiment specify a quantitative series of contemporaneous methamphetamine concentrations that could be used as a case-level elimination model.

A negative screening result is tied to a particular urine specimen, assay target, decision cutoff, and collection time. It does not confirm chemical absence from every bodily compartment, continuously document the intervening months, or retrospectively identify the date of the last exposure. Accordingly, the study should be described as an observation of a selected group in reported protracted abstinence, not a time-validated biological clock measuring a specific person’s last methamphetamine use.

What did the cognitive screening scores show?

The Montreal Cognitive Assessment (MoCA) is a brief standardized cognitive screen. Average total scores were 28.34 ± 2.24 in controls and 22.28 ± 3.70 in abstinent patients (means ± participant standard deviations), a reported between-group difference with p<.001 and Cohen’s d=2.02. This is a substantial separation in the sample, but MoCA is not a comprehensive neuropsychological battery and does not measure operational driving safety.

The authors reported lower scores for visuospatial/executive function, attention, abstraction, and delayed recall. However, they did not find statistically significant differences for naming (p=.287), language (p=.080), or orientation (p=.847). Selective domain-level null results are as important as the overall finding: the evidence does not warrant saying every cognitive ability was equally reduced. Several MoCA subdomains also have restricted score ranges and ceiling effects, making fine-grained interpretations particularly vulnerable to measurement noise.

Evidence table 1: what actually differed, and what did not?

These are values from the study’s original Table 1, not scores predicted for an unknown person. The statistical unit for each row is the participant, not a test item, scan voxel, or repeated brain volume. A nonsignificant group comparison also is not proof that the two groups are identical on that ability.

What is resting-state fMRI actually measuring?

Functional MRI uses the blood-oxygen-level-dependent (BOLD) signal, an indirect hemodynamic correlate of neural activity. People lie in a scanner without performing the study’s cognitive tasks while a time series of images is acquired. In this experiment, imaging used a 3.0-tesla system, with a repetition time of 2,000 milliseconds and 230 functional time points acquired per scan. Preprocessing removed the initial ten volumes and included slice-time correction, motion control, normalization, smoothing, and nuisance-signal handling.

The resulting measurements are calculated signal patterns in brain tissue. They are not a liquid biological sample and are not obtained by extracting and assaying parent methamphetamine molecules. Even a reproducible functional-connectivity difference cannot be converted into a venous whole-blood concentration in ng/mL without a separate, validated chemical relationship that this study did not establish.

How do fALFF and ReHo differ from functional connectivity?

The fractional amplitude of low-frequency fluctuations (fALFF) quantifies the proportion of slow signal fluctuations in a given imaging location. Regional homogeneity (ReHo) summarizes how similarly a voxel’s time series behaves relative to those of nearby voxels. Neither is a direct count of firing neurons, a measurement of transmitter concentration, or a substance-specific molecular signature.

In this sample, patients showed lower fALFF in the left fusiform gyrus, left calcarine cortex, right inferior frontal gyrus pars triangularis, and left supramarginal gyrus. They also showed lower ReHo in a large cluster centered on the right inferior frontal gyrus pars triangularis. The authors used voxel-level thresholds coupled with cluster-level family-wise-error correction, but the voxel thresholds differed by analysis: p<.005 for fALFF and seed connectivity, compared with p<.05 for ReHo. Interpreting one colorful image as an absolute map of damaged brain cells would go beyond the measurements.

Why was the right hippocampus selected?

The investigators chose the right hippocampus in advance as a seed region because of its roles in contextual and memory-related processing. They computed correlations between the seed time series and time series from other brain areas, producing a map of statistical coupling. Relative to controls, the abstinent group had stronger calculated right-hippocampal connectivity with the right inferior temporal gyrus, left inferior occipital gyrus, right thalamus, left angular gyrus, left inferior parietal lobule, right middle frontal gyrus, and left superior medial frontal gyrus.

The original Table 4 displays negative t-values for these differences because the authors defined the contrast as controls minus patients. Those signs must not be misread as weaker connectivity in patients. The anatomical names and directions depend on how the comparison is encoded. This is one reason forensic analysis should consult the actual table and its footnote, not rely on an isolated figure caption or abstract sentence.

Did greater hippocampal connectivity correspond to better cognition?

Yes, within the 25 abstinent patients, some right-hippocampal functional-connectivity measures correlated positively with MoCA scores after age and education were accounted for. The strongest reported association was between the right hippocampus and right inferior temporal gyrus: partial r=.765 for total MoCA, with false-discovery-rate-adjusted p=.00035. Other reported associations included connections to the left inferior occipital gyrus, left angular gyrus, and right middle frontal gyrus.

That correlation does not mean 76.5% of an individual’s impairment can be identified from a scan. Nor does it assign a causal effect to methamphetamine exposure. It relates continuous measures within a small selected clinical cohort, and the study did not test a predictive model on new patients. In particular, there were no blinded sensitivity and specificity estimates for diagnosing recent methamphetamine use from a single subject’s connectivity map.

Evidence table 2: which corrected network–cognition associations were reported?

These are selected original Table 6 associations that survived the study’s specified false-discovery-rate procedure; the underlying sample was only 25 patients. Other imaging relationships were examined without entering this list. Their omission should not be described as a reported nonsignificant result unless their actual test result is available.

Were the connectivity–cognition relationships different between groups?

The investigators used interaction models comparing the slopes of connectivity–cognition relationships in patients and controls while including age and education. For right hippocampus to right inferior temporal gyrus connectivity and total MoCA, the reported group-by-connectivity interaction was β=9.30, 95% confidence interval 2.09 to 16.51, p=.013. The clinical-group within-group correlation was .765, compared with a reported .533 in controls. Interactions were also reported for attention with left angular gyrus connectivity (p=.006) and for several other selected scores.

Those interaction estimates are slopes in a model whose underlying brain-connectivity units differ from a standard concentration unit. The source specifies false-discovery-rate correction for selected within-group correlations, but its interaction table lists p-values without the same explicit adjusted-p column. The distinction matters when many network–outcome comparisons are considered. Statistical interaction is neither a patient-level classifier nor evidence that one connection caused cognitive scores to change.

Did the larger resting-state networks show one uniform pattern?

No. Independent component analysis estimated activity patterns for networks such as the auditory, default-mode, and somatomotor systems. In the auditory network, the controls had stronger calculated intrinsic connectivity in bilateral precentral/postcentral areas. In the posterior default-mode component, controls had stronger connectivity in a right middle temporal region, whereas in an anterior component patients had stronger connectivity in a left superior frontal region. In the somatomotor network, controls showed stronger connectivity in a right superior frontal region.

This mixed directionality limits a simplistic story that abstinence uniformly lowers or uniformly raises neural coupling. Separate analytic pipelines can capture distinct spatial scales and physiological sources of variation. Stronger signal correlation in one pathway need not mean healthier or more efficient neural activity, just as a lower local fluctuation measure does not establish cellular injury. The study was designed to characterize associations, not to prove the mechanism that produced them.

Could stronger connectivity represent compensation, damage, or both?

The authors discussed an interpretation they described as potentially inefficient compensatory hyperconnectivity: enhanced dependence on some hippocampal-centered pathways might coexist with reduced local synchronization elsewhere. That is an interpretive hypothesis, not an experimentally demonstrated biological mechanism. Resting-state measurements alone cannot show whether the increased coupling began before substance use, resulted from prior methamphetamine exposure, developed during abstinence, or reflects another clinical or environmental characteristic.

Testing compensation would require longitudinal observations, detailed exposure histories, functional outcomes, or interventions that alter the putative mechanism and measure subsequent change. This experiment did not follow these 54 individuals across recovery time points. Its cross-sectional comparison should not be converted into an assertion of permanent damage, inevitable improvement, complete recovery, or a prescribed treatment target for any one person.

What limits generalization to forensic cases?

Several limitations converge. The retained clinical sample was 25 men, not a large representative population. Detailed lifetime methamphetamine dose, frequency, severity, and duration were not systematically collected. The approximate three-to-twelve-month abstinence window was not precise enough for a day-level duration analysis. A single MoCA screening assessment supplied the cognitive benchmark rather than a detailed battery of reaction time, divided attention, lane tracking, psychomotor control, and decision-making tasks.

Furthermore, fMRI BOLD measures are influenced by hemodynamic factors, acquisition and preprocessing choices, movement, and multiple-comparison decisions. The original authors excluded six scans for movement or quality reasons, illustrating that data quality itself affects what enters the analysis. The patient and control groups were not created by randomizing healthy volunteers to long-term methamphetamine use, so their cross-sectional differences cannot isolate substance exposure from all other possible causes.

How should an attorney or toxicologist use this study?

The defensible use is to describe a research finding: in a selected clinical group reporting protracted methamphetamine abstinence, particular screening scores and resting-state functional-connectivity features differed from healthy controls. That may help frame questions about the scientific literature on persistent cognitive correlates of substance-use history. It does not by itself determine the truth of a witness’s statement, whether a driver was impaired, the drug’s concentration at a collision, or whether a defendant’s particular behavior was caused by prior use.

For a chemical toxicology assertion, examine the actual specimen and its validated analytical record. Was the matrix venous whole blood, physically separated plasma or serum, urine, oral fluid, or another sample? Was parent methamphetamine identified and quantified, or was only a screening test performed? What were the analyte, cutoff, uncertainty, collection time, and chain of custody? Our site’s biological-matrices guide and confirmatory-testing guide explain why the matrix and method must remain connected to the conclusion.

For an impairment assertion, additional contemporaneous behavior, clinical observations, timing evidence, other substances, medical context, and relevant legal standards must be evaluated. A statistical association between an imaging signal and a screening score cannot substitute for those facts. The therapeutic-drug-monitoring guide further illustrates why dosing history and a physically measured concentration are separate concepts.

Seven frequently asked questions

1. Can this fMRI pattern identify someone who took methamphetamine?

No. The study compared preselected groups and did not derive or prospectively validate an individual drug-identification classifier. Resting-state connectivity is not a molecule-specific assay. The source provided no case-level diagnostic sensitivity, specificity, likelihood ratios, or forensic decision threshold.

2. Were methamphetamine levels measured in whole blood or plasma?

No quantitative parent-methamphetamine concentration in venous whole blood, serum, or plasma was reported for this experiment. The enrollment and scan-day negative urine screens were used to support reported abstinence, not to produce a drug concentration time series. The principal biological measurement was the brain’s BOLD imaging signal.

3. Does a MoCA score of 22.28 describe every former user?

No. It is the mean in 25 selected male patients, with a standard deviation of 3.70. Individual distributions can overlap, and this mean cannot be assigned to a different person without testing. It also does not represent a validated threshold for unsafe driving or impaired testimony.

4. Why is the hippocampal correlation positive when patients scored lower?

These are different comparisons. Patients as a group had lower cognitive screening scores than controls, while within the patient group individuals showing stronger calculated hippocampal–temporal coupling tended to have higher MoCA scores. Both findings can be true without proving that the coupling caused better performance or restored normal functioning.

5. Did all cognitive screening subtests show significant differences?

No. Naming, language, and orientation comparisons were not statistically significant in the original group analysis. Differences did emerge for the overall score and selected other subdomains. Such nulls should be reported alongside the significant findings, without asserting that a nonsignificant test proves identical cognitive capacity.

6. Can these scans determine whether someone has been abstinent for six months?

No. The study did not calibrate neuroimaging patterns against verified last-use dates. Participants reported roughly three to twelve months of abstinence, with limited urine screening at specified times. The authors explicitly lacked reliable exact dates and did not establish an imaging clock for recovery or abstinence verification.

7. Does hippocampal hyperconnectivity prove a permanent methamphetamine injury or an individual’s legal impairment?

No. The cross-sectional data cannot establish whether a pattern predates use, follows use, reflects compensation, or changes over time. There was no driving experiment, measured individual forensic blood level, or specific incident. Persistent-history associations warrant research, not automatic person-specific causation or legal conclusions.

Bottom line: research association is not a personal forensic test

In a carefully specified 54-man observational sample, resting-state brain signals and MoCA screening scores differed across groups, and selected right-hippocampal connections correlated with cognition within 25 abstinent patients. Equally important are the nonsignificant subdomains, imperfect exposure histories, small cross-sectional sample, and absence of direct chemical drug quantitation or driving outcomes. The study can inform a literature review about brain networks after methamphetamine use disorder. It cannot identify a person’s blood methamphetamine level, reconstruct the timing of past use, certify impairment, or decide the cause of a litigated event.

Primary scientific source: Yang et al., BMC Psychiatry (2026), 26:710.